Invest in the future of period care

Why invest in Meliodays?

MelioOne® is a Bold Solution to a Universal Problem.

Meliodays is pioneering MelioOne®, the first non-contraceptive non-hormonal IUD designed for period pain. It’s a first-in-class therapeutic device targeting a massive unmet need in menstrual health, with validated early traction, a clear regulatory pathway, and a scalable commercial model. 

  • 1 in 3 women suffer from severe menstrual pain—few safe, effective options exist 

  • High-impact, scalable, IP-led opportunity in a € 50 B+ FemTech market 

  • Early prototyping in progress 

  • Market validation by 800+ women and ongoing validation by gynecologists 

  • Backed by experts, specializing in the healthcare market 

  • Led by a mission to close the gender health gap 

How to invest in Meliodays?

There are two ways to invest, as a professional investor or as an individual or impact investor.

To professional investors seeking to explore our full business case, request a pitch deck below, and our Investor Relations team will reach out to you accordingly. Alternatively, feel free to email us at ir@meliodays.com

Professional Investor

Meliodays presents a unique opportunity to invest early in a FemTech category creator with high clinical relevance, validated demand, and clear commercial scalability. With a non-hormonal IUD designed specifically for menstrual pain, we’re targeting a vast and underserved market with an innovative delivery model backed by medical insight and community-led design.

Here’s why this is a category-defining opportunity:

  • High Unmet Need
    Dysmenorrhea affects up to 91% of women globally. Current treatments are often ineffective or poorly tolerated. MelioOne offers targeted, non-hormonal, long-term pain relief.

  • Data-Led Innovation with Clinical Backbone
    800+ women surveyed with ongoing validation study among gynecologists and adolescents underway. First known product under development to deliver localized NSAIDs via an IUD platform. Familiar mechanism, novel application.

  • Fast-Growing Opportunity with Clear Path to Market
    Prototype in development. Product launch targeted for Q2 2029 in line with FemTech growth projection to exceed €103B by 2030. Over 600M lost work hours annually from menstrual pain in the U.S. alone.

  • Backed & Building Momentum
    Pre-seed closed with impact VC Capacura. Preparing for seed-stage fundraising.

Individual / Impact Investor

Meliodays offers a powerful opportunity to invest in health equity by supporting a first-of-its-kind product designed specifically for women’s pain—without hormones, without shame, and without compromise. With MelioOne®, we are addressing a widespread but under-recognised health issue through innovation that centres lived experience, accessibility, and inclusion.

Our product, MelioOne®, is a non-hormonal IUD designed exclusively to relieve period pain. It’s not for contraception. It’s for care.

  • Why It Matters
    Period pain affects up to 91% of women. Hormonal and oral NSAID treatments are often unsuitable or poorly tolerated. The gender health gap is persistent and systemic.

  • Our Approach
    Built with 800+ women through co-creation. Ongoing validation with clinicians. Designed to fit into women’s lives.

  • Impact ROI
    Supports adolescents in education and well-being. Avoids systemic or hormonal side effects. Empowers choice, equity, and access.

Meliodays is for those who believe innovation should serve the underserved. And that pain—especially women’s pain—deserves better. As an impact investor, you may choose to invest in MelioOne’s journey to market from €1,000 via our main investor and impact VC firm, Capacura.


Invest via Capacura

Thank you for your interest. 

We’re building more than a product—we’re finding a better approach to women’s health. If our mission resonates with you, we invite you to explore the links below to dive deeper into our solution, mission and what makes Meliodays unique.